Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

Completed · Early Phase 1 · Has a placebo group

Conditions studied: Methamphetamine Abuse, Methamphetamine Dependence

In brief

The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of combined oxazepam and naltrexone for managing methamphetamine dependence.

Key facts

Study ID
NCT01967381
Run by
University of Kentucky
People needed
24
Starts
2013-10-01
Expected to finish
2018-09-01
Last updated by the study team
2018-09-14

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.